Hemoglobinopathy Retinopathy Medication

  • Author: Brian A Phillpotts, MD; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: Feb 16, 2012
 

Medication Summary

See Special Concerns and Surgical Care.

Next

Hemostatic agents

Class Summary

Reduce the incidence of rebleeds in the setting of hyphema.

View full drug information

Aminocaproic acid (Amicar)

 

Inhibits fibrinolysis via inhibition of plasminogen activator substances; to a lesser degree, through antiplasmin activity.

Main problem is that the thrombi that form during treatment are not lysed, and effectiveness is uncertain.

Previous
Next

Corticosteroids

Class Summary

Reduce the incidence of rebleeds in the setting of hyphema.

View full drug information

Prednisolone 1% (Pred Forte)

 

Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.

View full drug information

Prednisone (Deltasone, Orasone, Meticorten)

 

May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Brian A Phillpotts, MD  Former Vitreo-Retinal Service Director, Former Program Director, Clinical Assistant Professor, Department of Ophthalmology, Howard University College of Medicine

Brian A Phillpotts, MD is a member of the following medical societies: American Academy of Ophthalmology, American Diabetes Association, American Medical Association, and National Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Hon-Vu Q Duong, MD  Clinical Instructor of Ophthalmology and Ophthalmic Pathology, Westfield Eye Center

Hon-Vu Q Duong, MD is a member of the following medical societies: American Academy of Ophthalmology

Disclosure: Nothing to disclose.

Michael J Shapiro, MD  Associate Professor, Vitreoretinal Service, Director, Eye Trauma Services, Department of Ophthalmology, University of Illinois at Chicago; Vitreoretinal Consultant, Pediatric Genetics and Birth Defects Clinic

Michael J Shapiro, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Oswaldo Castro, MD  Senior Advisor, Center for Sickle Cell Disease, Professor Emeritus of Medicine and Pediatrics, College of Medicine

Disclosure: Nothing to disclose.

Richard G Fiscella, PharmD, MPH  Clinical Professor, Department of Pharmacy and Ophthalmology, University of Illinois at Chicago

Disclosure: Nothing to disclose.

Specialty Editor Board

Russell P Jayne, MD  Consulting Vitreoretinal Surgeon, The Retina Center at Las Vegas

Russell P Jayne, MD is a member of the following medical societies: American Medical Association, American Society of Cataract and Refractive Surgery, and American Society of Retina Specialists

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Steve Charles, MD  Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine; Adjunct Professor of Ophthalmology, Columbia College of Physicians and Surgeons; Clinical Professor Ophthalmology, Chinese University of Hong Kong

Steve Charles, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Club Jules Gonin, Macula Society, and Retina Society

Disclosure: Alcon Laboratories Consulting fee Consulting; OptiMedica Ownership interest Other; Topcon Medical Lasers Consulting fee Consulting

Lance L Brown, OD, MD  Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

References

  1. Leveziel N, Bastuji-Garin S, Lalloum F, Querques G, Benlian P, Binaghi M, et al. Clinical and laboratory factors associated with the severity of proliferative sickle cell retinopathy in patients with sickle cell hemoglobin C (SC) and homozygous sickle cell (SS) disease. Medicine (Baltimore). Nov 2011;90(6):372-8. [Medline].

  2. Cho M, Kiss S. Detection and monitoring of sickle cell retinopathy using ultra wide-field color photography and fluorescein angiography. Retina. Apr 2011;31(4):738-47. [Medline].

  3. Hanscom TA. Indirect treatment of peripheral retinal neovascularization. Am J Ophthalmol. Jan 1982;93(1):88-91. [Medline].

  4. Nasrullah A, Kerr NC. Sickle cell trait as a risk factor for secondary hemorrhage in children with traumatic hyphema. Am J Ophthalmol. Jun 1997;123(6):783-90. [Medline].

  5. Acheson RW, Ford SM, Maude GH, et al. Iris atrophy in sickle cell disease. Br J Ophthalmol. Jul 1986;70(7):516-21. [Medline].

  6. Aessopos A, Voskaridou E, Kavouklis E, et al. Angioid streaks in sickle-thalassemia. Am J Ophthalmol. May 15 1994;117(5):589-92. [Medline].

  7. Andreoli TE, et al. Disorder of red cells. In: Cecil's Essentials of Medicine. 4th ed. 1997:383-7.

  8. Asdourian GK. Sickle cell retinopathy. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. Vol 2. 1994:1006-1018.

  9. Beutler E. Disorders of hemoglobin. In: Fauci AS, et al, eds. Harrison's Principle of Internal Medicine. 14th ed. 1998:645-652.

  10. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. Sep 11 1997;337(11):762-9. [Medline].

  11. Charache S. Eye disease in sickling disorders. Hematol Oncol Clin North Am. Dec 1996;10(6):1357-62. [Medline].

  12. Cohen SB, van Houten PA. Hemoglobinopathies. In: Ryan SJ, et al, eds. Retina. 2nd ed. 1994:1465-1472.

  13. Eagle RC. Retina-sickle hemoglobinopathy. In: Eye Pathology: An Atlas and Basic Text. 1999:147, 153-4.

  14. Farber MD, Fiscella R, Goldberg MF. Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology. Mar 1991;98(3):279-86. [Medline].

  15. Farber MD, Jampol LM, Fox P, et al. A randomized clinical trial of scatter photocoagulation of proliferative sickle cell retinopathy. Arch Ophthalmol. Mar 1991;109(3):363-7. [Medline].

  16. Fekrat S, Lutty G, Goldberg M. Retina-Vitreous Macula. In: Guyer D, et al. Hemoglobinopathies. Vol 1. 1999:438-458.

  17. Fox PD, Dunn DT, Morris JS, et al. Risk factors for proliferative sickle retinopathy. Br J Ophthalmol. Mar 1990;74(3):172-6. [Medline].

  18. Gagliano DA, Goldberg MF. The evolution of salmon-patch hemorrhages in sickle cell retinopathy. Arch Ophthalmol. Dec 1989;107(12):1814-5. [Medline].

  19. Goldbert MF. Duane's Clinical Ophthalmology. In: Tasman W and Jaeger EA. Sickle Cell Retinopathy. Vol 3. 1990:1-45.

  20. Green WR. Retina: Systemic Diseases with Retinal Involvement. In: Spencer WH. Ophthalmic Pathology: An Atlas and Textbook. Vol 2. 1996:1155-1160.

  21. Jacobson MS, Gagliano DA, Cohen SB, et al. A randomized clinical trial of feeder vessel photocoagulation of sickle cell retinopathy. A long-term follow-up. Ophthalmology. May 1991;98(5):581-5. [Medline].

  22. Jampol LM. Arteriolar occlusive diseases of the macula. Ophthalmology. May 1983;90(5):534-9. [Medline].

  23. Jampol LM. Vitrectomy surgery in proliferative sickle retinopathy. Am J Ophthalmol. Nov 15 1987;104(5):553-4. [Medline].

  24. Jampol LM, Green JL Jr, Goldberg MF, et al. An update on vitrectomy surgery and retinal detachment repair in sickle cell disease. Arch Ophthalmol. Apr 1982;100(4):591-3. [Medline].

  25. Kark JA, Posey DM, Schumacher HR, et al. Sickle-cell trait as a risk factor for sudden death in physical training. N Engl J Med. Sep 24 1987;317(13):781-7. [Medline].

  26. Kimmel AS, Magargal LE, Stephens RF, et al. Peripheral circumferential retinal scatter photocoagulation for the treatment of proliferative sickle retinopathy. An update. Ophthalmology. Nov 1986;93(11):1429-34. [Medline].

  27. Liebmann JM. Management of sickle cell disease and hyphema. J Glaucoma. Aug 1996;5(4):271-5. [Medline].

  28. Lubin BH. Sickle cell disease and the endothelium. N Engl J Med. Nov 27 1997;337(22):1623-5. [Medline].

  29. McLeod DS, Goldberg MF, Lutty GA. Dual-perspective analysis of vascular formations in sickle cell retinopathy. Arch Ophthalmol. Sep 1993;111(9):1234-45. [Medline].

  30. McLeod DS, Merges C, Fukushima A, et al. Histopathologic features of neovascularization in sickle cell retinopathy. Am J Ophthalmol. Oct 1997;124(4):455-72. [Medline].

  31. Morgan CM, D'Amico DJ. Vitrectomy surgery in proliferative sickle retinopathy. Am J Ophthalmol. Aug 15 1987;104(2):133-8. [Medline].

  32. Palmer DJ, Goldberg MF, Frenkel M, et al. A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology. Jan 1986;93(1):102-8. [Medline].

  33. Pulido JS, Flynn HW Jr, Clarkson JG, et al. Pars plana vitrectomy in the management of complications of proliferative sickle retinopathy. Arch Ophthalmol. Nov 1988;106(11):1553-7. [Medline].

  34. Raichand M, Dizon RV, Nagpal KC, et al. Macular holes associated with proliferative sickle cell retinopathy. Arch Ophthalmol. Sep 1978;96(9):1592-6. [Medline].

  35. Rednam KR, Jampol LM, Goldberg MF. Scatter retinal photocoagulation for proliferative sickle cell retinopathy. Am J Ophthalmol. May 1982;93(5):594-9. [Medline].

  36. Serjeant GR. Sickle-cell disease. Lancet. Sep 6 1997;350(9079):725-30. [Medline].

  37. Siegel D. Diagnosis and treatment of sickle cell retinopathy. J Am Optom Assoc. Nov 1988;59(11):885-8. [Medline].

  38. Slavin ML, Barondes MJ. Ischemic optic neuropathy in sickle cell disease. Am J Ophthalmol. Feb 15 1988;105(2):212-3. [Medline].

  39. Stryer L. Oxygen-transporting proteins: myoglobin and hemoglobin. In: Biochemistry. 3rd ed. 1988:143-173.

  40. To KW, Nadel AJ. Ophthalmologic complications in hemoglobinopathies. Hematol Oncol Clin North Am. Jun 1991;5(3):535-48. [Medline].

  41. van Meurs JC. Evolution of a retinal hemorrhage in a patient with sickle cell-hemoglobin C disease. Arch Ophthalmol. Aug 1995;113(8):1074-5. [Medline].

  42. Yanoff M, Fine BS. Sickle cell disease. In: Ocular Pathology. 4th ed. 1996:377-8.

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.